NO971003L - Enteral vaccine against vaginal infections - Google Patents

Enteral vaccine against vaginal infections

Info

Publication number
NO971003L
NO971003L NO971003A NO971003A NO971003L NO 971003 L NO971003 L NO 971003L NO 971003 A NO971003 A NO 971003A NO 971003 A NO971003 A NO 971003A NO 971003 L NO971003 L NO 971003L
Authority
NO
Norway
Prior art keywords
vaccine against
adjuvant
vaginal infections
enteral
against vaginal
Prior art date
Application number
NO971003A
Other languages
Norwegian (no)
Other versions
NO971003D0 (en
Inventor
Robert Llewellyn Clancy
Original Assignee
Auspharm Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspharm Int Ltd filed Critical Auspharm Int Ltd
Publication of NO971003D0 publication Critical patent/NO971003D0/en
Publication of NO971003L publication Critical patent/NO971003L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)

Abstract

Enteral vaksine mot vaginale infeksjoner Enteral vaksine uten tilsetning av adjuvans omfattende en drept mikro- organisme som infiserer vagina. Mikro- organismen kan være en sopp, slik som Candida albicans, en bakterie, slik som Gardnerella vaginalls eller Nelsseria gonorrhoea, en protozo, slik som Tri- chomonas vaginalls, eller et virus, slik som Herpes genitalis. Fravær av adjuvans gir en signifikant forbedring med hensyn til fjerning av mikroorga- nismene sammenlignet med preparater med tilsetning av adjuvans.Enteral vaccine against vaginal infections Enteral vaccine without the addition of adjuvant comprising a killed microorganism that infects the vagina. The microorganism may be a fungus, such as Candida albicans, a bacterium, such as Gardnerella vaginalls or Nelsseria gonorrhoea, a protozoa, such as Trichomonas vaginalls, or a virus such as Herpes genitalis. Absence of adjuvant provides a significant improvement in the removal of microorganisms compared to adjuvant addition preparations.

NO971003A 1994-09-06 1997-03-05 Enteral vaccine against vaginal infections NO971003L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417880A GB9417880D0 (en) 1994-09-06 1994-09-06 Vaccine
PCT/IB1995/000766 WO1996007426A1 (en) 1994-09-06 1995-09-05 Enteral vaccine for vaginal infections

Publications (2)

Publication Number Publication Date
NO971003D0 NO971003D0 (en) 1997-03-05
NO971003L true NO971003L (en) 1997-05-06

Family

ID=10760876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971003A NO971003L (en) 1994-09-06 1997-03-05 Enteral vaccine against vaginal infections

Country Status (12)

Country Link
EP (1) EP0779817A1 (en)
JP (1) JPH10505083A (en)
KR (1) KR970705409A (en)
CN (1) CN1159760A (en)
AU (1) AU3353095A (en)
CA (1) CA2199255A1 (en)
FI (1) FI970933A (en)
GB (1) GB9417880D0 (en)
IL (1) IL115197A (en)
NO (1) NO971003L (en)
WO (1) WO1996007426A1 (en)
ZA (1) ZA957482B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834322A3 (en) * 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mycosis vaccine
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
ATE476987T1 (en) * 2000-06-19 2010-08-15 Hunter Immunology Ltd COMPOSITIONS AND METHODS FOR TREATING CANDIDASIS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL49459A (en) * 1975-04-25 1980-02-29 Bactex Inc Gonococcal pilin and other materials isolated from pili of neisseria gonorrhoeae compositions and vaccines containing them and method of testing the presence of antibodies to n. gonorrhoeae pili
ZA767577B (en) * 1976-01-29 1977-11-30 American Cyanamid Co Method of extracting and using antigen and products prepared therefrom
FR2397839A1 (en) * 1977-07-18 1979-02-16 Grimberg Georges Oral vaccine for treating or preventing gastroenteritis - comprises specified killed or attenuated microorganisms
US4220638A (en) * 1978-10-12 1980-09-02 Merck & Co., Inc. Antigenic complex from N. Gonorrhoeae
US4443431A (en) * 1981-05-27 1984-04-17 The United States Of America As Represented By The Department Of Health And Human Services Neisseria gonorrhoeae vaccine
GB8506373D0 (en) * 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
DD268868A1 (en) * 1987-04-03 1989-06-14 Forsch Lungenkrankheiten Und T METHOD FOR BETTER MANUFACTURE OF LOCALLY BIOLOGICAL PRACTICES
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine

Also Published As

Publication number Publication date
GB9417880D0 (en) 1994-10-26
FI970933A (en) 1997-05-05
FI970933A0 (en) 1997-03-05
IL115197A (en) 1999-07-14
NO971003D0 (en) 1997-03-05
ZA957482B (en) 1997-03-06
CA2199255A1 (en) 1996-03-14
MX9701730A (en) 1997-10-31
WO1996007426A1 (en) 1996-03-14
EP0779817A1 (en) 1997-06-25
IL115197A0 (en) 1995-12-31
CN1159760A (en) 1997-09-17
JPH10505083A (en) 1998-05-19
KR970705409A (en) 1997-10-09
AU3353095A (en) 1996-03-27

Similar Documents

Publication Publication Date Title
CA2132833A1 (en) Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a
NZ337885A (en) vaccine formulation of an antigen, a TH-1 inducing adjuvant and a sparingly water soluble amino acid
WO2001068103A3 (en) Treatment of herpes infection using immunomodulatory polynucleotide sequences
BR9912653A (en) Attenuated herpes virus, virus strain, dendritic cell, process to produce a cell, pharmaceutical composition, use of a virus, and process to perform gene therapy on a human or animal patient or to treat or prevent a pathogenic infection or cancer to treat animal patient
DK0759089T3 (en) Treatment of Glucans with Enzymes
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
WO1991003248A3 (en) Method for immune system activation
DE69839699D1 (en) VAGINAL LACTOBACILLUS MEDICAMENT
BR9712366A (en) Herpes simplex hsv2 gd2 gene isolated, plasmid comprising the same, and processes to induce an immune response against hsv2 gd2 in an individual, to treat an individual who is infected with hsv, and to prevent an individual from becoming infected with hsv
DE3850649D1 (en) IMMUNOTHERAPEUTIC PREPARATIONS FOR THE TREATMENT OF AIDS.
GR3017128T3 (en) Treatment of hiv infections and compounds useful therein.
DE69533673D1 (en) TREATMENT AND PREVENTION OF HELICOBACTER INFECTIONS
NO883594D0 (en) PROCEDURE FOR THE PREPARATION OF DOUBLE WIRED RNA PREPARATIONS.
AU2053688A (en) Topically active compositions of double-stranded rnas
ES8802209A1 (en) Vaccine system
DK312688A (en) GLYKKOPEPTID antibiotics
NO971003L (en) Enteral vaccine against vaginal infections
Donahoe et al. Neutralization of the Phagocytosis-Enhancing Acitivity of Interferon Preparations by Anti-Interferon Serum
PT859613E (en) UTILIZATION OF FLUPIRTIN FOR PROPHYLAXIS AND THE TREATMENT OF DISEASES ASSOCIATED WITH AN ALTERATION OF THE HEMATOPOIETIC CELL SYSTEM
EA200200704A1 (en) IMMEDIATE MICROORGANISMS FOR THE TREATMENT OF INFECTION
UA41338C2 (en) Method for inhibiting retroviral infection caused by human immunodeficiency virus (hiv), method for inhibiting human immunodeficiency virus (hiv)
Manire et al. The chlamydiae.
CA2394843A1 (en) A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
EP1143981A4 (en) Treatment and prevention of hiv and other viral infections
AU2211592A (en) Method of treatment for latent virus infection